Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	FGFR2 Y375C
Gene Variant Detail	FGFR2 Y375C (gain of function)
Relevant Treatment Approaches	FGFR Inhibitor (Pan) FGFR2 Inhibitor

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 18 of 18 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR2 Y375C	salivary gland carcinoma	predicted - sensitive	FGFR2 Inhibitor	Lirafugratinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (ReFocus), Lirafugratinib treatment resulted in a partial response with near complete resolution of liver metastases, and regression of lung and adrenal metastases in a patient with metastatic carcinoma of the right parotid salivary gland harboring FGFR2 Y375C (PMID: 37270847; NCT04526106).	37270847
FGFR2 Y375C	salivary gland cancer	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in a complete response with a duration of response of 5.75 months in one patient and a partial response with a duration of response of 13.47 months in another patient, both with salivary gland cancer harboring FGFR2 Y375C (PMID: 37541273; NCT04083976).	37541273
FGFR2 Y375C	lung non-squamous non-small cell carcinoma	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in a complete response with a duration of response of 5.59 months in a patient with non-squamous non-small cell lung cancer harboring FGFR2 Y375C (PMID: 37541273; NCT04083976).	37541273
FGFR2 Y375C	endometrial cancer	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in a partial response with a duration of response of 6.9 months in a patient with endometrial cancer harboring FGFR2 Y375C (PMID: 37541273; NCT04083976).	37541273
FGFR2 Y375C	intrahepatic cholangiocarcinoma	predicted - sensitive	FGFR Inhibitor (Pan)	Futibatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lytgobi (futibatinib) treatment resulted in a partial response with a progression-free survival of 35.5 months and a best objective response of -45% in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 Y375C (reported as Y376C) (PMID: 39226398).	39226398
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	FGFR Inhibitor (Pan)	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).	34272467
FGFR2 Y375C	Advanced Solid Tumor	predicted - resistant	FGFR Inhibitor (Pan)	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FGFR2 Y375C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).	34272467
FGFR2 Y375C	breast cancer	sensitive	FGFR Inhibitor (Pan)	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lytgobi (futibatinib) inhibited Fgfr2 signaling and viability in breast epithelial cells expressing FGFR2 Y375C in culture (PMID: 37980453).	37980453
FGFR2 Y375C	breast cancer	sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited viability of breast epithelial cells expressing FGFR2 Y375C in culture (PMID: 37980453).	37980453
FGFR2 Y375C	breast cancer	sensitive	FGFR Inhibitor (Pan)	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited viability of breast epithelial cells expressing FGFR2 Y375C in culture (PMID: 37980453).	37980453
FGFR2 Y375C	breast cancer	sensitive	FGFR Inhibitor (Pan)	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited viability of breast epithelial cells expressing FGFR2 Y375C in culture (PMID: 37980453).	37980453
FGFR2 Y375C	cholangiocarcinoma	sensitive	FGFR Inhibitor (Pan)	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lytgobi (futibatinib) inhibited viability of a cholangiocyte cell line harboring FGFR2 Y375C in culture (PMID: 37980453).	37980453
FGFR2 Y375C	breast cancer	sensitive	FGFR2 Inhibitor	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Pemazyre (pemigatinib) inhibited viability of breast epithelial cells expressing FGFR2 Y375C in culture (PMID: 37980453).	37980453

Showing 1 to 18 of 18 entries

Filter rows: